Fundraising Fox
Signacor
1 known investors
Find your way into Signacor
Sign up to see every warm intro you have to Signacor
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Signacor team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
SignaCor is a clinical-stage biotech company developing Cardiaza, a first-in-class injectable epigenetic (DNA methylation inhibiting) therapy for symptomatic hypertrophic cardiomyopathy that targets underlying disease mechanisms such as cardiac fibrosis rather than only symptoms. Spun out of Queen's University Belfast, the company focuses on therapeutics for cardiac disease.
Founders & leadership
DC
Dr Chris WatsonFounder
Investors · 1
Frequently asked questions
- What does Signacor do?
- SignaCor is a clinical-stage biotech company developing Cardiaza, a first-in-class injectable epigenetic (DNA methylation inhibiting) therapy for symptomatic hypertrophic cardiomyopathy that targets underlying disease mechanisms such as cardiac fibrosis rather than only symptoms. Spun out of Queen's University Belfast, the company focuses on therapeutics for cardiac disease.
- Who founded Signacor?
- Signacor was founded by Dr Chris Watson.
- Who are Signacor's investors?
- Signacor's investors include Clarendon Fund Managers Ltd..